Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

Date: May 16, 2025

To,
Corporate Relations Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001.

Scrip Code: 540788
Security ID: ASPIRA

Sub: Outcome of the meeting of Board of Directors held on Friday, May 16, 2025

Dear Sir/Madam,

In compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e. on Friday, May 16, 2025 inter alia, has considered, approved and taken on record the following matter(s):

1. Audited Financial Results of the Company along with the Audit Report for the quarter and year ended March 31, 2025. A copy of signed Results along with Auditors Report and Declaration in respect of Audit Report with unmodified opinion under Regulation 33 of the Listing Regulations is attached herewith.

2. Appointment of M/s. Nilesh A. Pradhan & Co. LLP, Practicing Company Secretary (Firm Registration No. L2018MH005200) as a Secretarial Auditor of the Company for the period of five (5) years i.e 2025-2026 to 2029-2030 subject to member's approval at the ensuing Annual General Meeting of the Company.

3. Appointment of M/s. Vishal J Bhanushali & Associates, Practicing Chartered Accountant (Firm Registration Number: 145806W), as an Internal Auditor of the Company for the Financial year 2025-2026.

4. Approval of re-appointment and payment of remuneration of Dr. Pankaj Shah (DIN: 02836324) as Managing Director & CEO of the Company for a period of Three (3) years commencing from August 01, 2025 to July 31, 2028 subject to approval of the shareholders of the Company

5. Approval of

Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

i) Issuance of Notice for Conducting Postal Ballot for the item no.4. Notice will be circulated in due course.

ii) Appointment of M/s. Nilesh A. Pradhan & Co. LLP as a Scrutinizer for the Postal Ballot.

iii) Record Date – 06.06.2025 to determine the eligible members, who are entitled to receive notice of Postal Ballot and to cast their vote on the matters stated in the Postal Ballot Notice through remote e-Voting facility.

The meeting of the Board of Directors commenced at 3.30 p.m. and concluded at 07.45 p.m.

Kindly take the same on record.

Thanking you

Yours Faithfully,
For **Aspira Pathlab and Diagnostics Limited**

NIKUNJ VELJI MANGE
Digitally signed by NIKUNJ VELJI MANGE
Date: 2025.05.16 19:50:44 +05'30'

Nikunj Mange
Executive Director

Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED BY THE BOARD OF DIRECTORS OF ASPIRA PATHLAB & DIAGNOSTICS LIMITED ("THE COMPANY") IN ITS MEETING HELD ON FRIDAY, MAY 16, 2025 COMMENCED AT 3.30 P.M (IST) AT DEXTRUS BKC CRESCENZO, MUMBAI-400051.

AUTHORISATION FOR SIGNING THE ADUITED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FINANCIAL YEAR ENDED MARCH 31, 2025

"**RESOLVED THAT** pursuant to regulation 33(2)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audited financial results for the fourth quarter and financial year ended March 31,2025 be and is hereby approved.

RESOLVED FURTHER THAT pursuant to regulation 33(2)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mr. Nikunj Mange, Executive Director (DIN: 08489442) of the Company be and is hereby authorised on behalf of the Board members to sign the aforesaid audited financial results for the fourth quarter and financial year ended March 31,2025".

For and on behalf of
Aspira Pathlab & Diagnostics Limited

NIKUNJ VELJI MANGE
Digitally signed by NIKUNJ VELJI MANGE
Date: 2025.05.16 19:52:21 +05'30'

_____

Nikunj Mange
Executive Director

Sarda Soni Associates LLP
CHARTERED ACCOUNTANTS

Manoj Jain
B.Com(H), FCA, ACS, IP(ICAI), RV(S&FA)

Independent Auditor's Report on Audit of Standalone Annual Financial Results of Aspira Pathlab & Diagnostics Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of
Aspira Pathlab & Diagnostics Limited

Opinion

We have audited the accompanying standalone annual financial results of **Aspira Pathlab & Diagnostics Limited**, for the year ended 31st March 2025, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (**"Listing Regulations"**).

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:
a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net loss and other comprehensive income and other financial information for the year ended 31 March 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (**"SAs"**) specified under section 143(10) of the Companies Act, 2013 (**"the Act"**). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the standalone annual financial results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

SARDA SONI ASSOCIATES LLP * CHARTERED ACCOUNTANTS * FIRM REGN. NO. [illegible] MUMBAI

11, Friend's Union Premises Co-operative Society Ltd., 2nd Floor, 227, P. D'Mello Road, Mumbai 400 001.
Phone: 022-2269 5289 ; Mobile: 98191 65816
Email: ssaaudit2102@gmail.com / sardasoniassociates2102@gmail.com
Nagpur (HO): "Chartered Square", Samrat Ashok Square, Saraipeth, Nagpur 400 009.
Phone: 0712-2726795, 2729471

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

The standalone annual financial results have been prepared on the basis of the standalone annual financial statements. The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/(loss) and other comprehensive income/(loss) and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error. In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

SARDA & CO. LLP. CHARTERED ACCOUNTANTS FIRM REGN. NO. 117235 W MUMBAI

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the Standalone Annual Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

The standalone annual financial results include the results for the quarter ended 31 March 2025 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.



For Sarda Soni Associates LLP
Chartered Accountant
Firm Reg. No- 117235W

Manoj Kumar Jain
Partner
Membership No.-120788
Place- Mumbai
Date- 16.05.2025
UDIN: 25120788BMIEFG7403

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086

Tel No. 022-71975756, Email:support@aspiradiagnostics.com, Website : www.aspiradiagnostics.com

Statement of Standalone Financial Results for the Quarter and Year ended 31st March, 2025

(Rupees in Lakhs)

Particulars	Quarter ended			Year ended	Year ended
	31-Mar-25 (Unaudited) (Refer Note 3)	31-Dec-24 (Unaudited) (Refer Note 3)	31-Mar-24 (Unaudited) (Refer Note 3)	31-Mar-25 (Audited)	31-Mar-24 (Audited)
1. Income					
(a) Revenue from Operations	577.67	540.74	381.79	2,199.90	1,320.49
(b) Other Income	13.04	8.86	7.60	38.89	42.11
Total income	**590.71**	**549.61**	**389.40**	**2,238.79**	**1,362.60**
2. Expenses					
(a) Cost of Materials consumed	86.95	84.89	71.55	369.58	262.28
(b) Laboratory Testing Charges	25.09	22.41	21.47	99.65	74.41
(c) Employee benefits expense	194.41	196.57	163.65	732.62	619.80
(d) Finance Costs	9.32	9.41	8.46	34.74	36.77
(e)Depreciation and amortisation expense	36.74	38.59	37.59	149.38	153.88
(f)Other expenses	165.87	160.07	136.95	645.57	482.69
Total Expenses	**518.37**	**511.94**	**439.66**	**2,031.53**	**1,629.82**
3. Profit / (Loss) before exceptional items and tax (1-2)	**72.33**	**37.66**	**(50.26)**	**207.26**	**(267.22)**
4. Exceptional Items	-	-	-	-	-
5. Profit / (Loss) before tax (3+4)	**72.33**	**37.66**	**(50.26)**	**207.26**	**(267.22)**
6. Tax Expenses	-	-	-	-	-
7. Profit / (Loss) after tax (5-6)	**72.33**	**37.66**	**(50.26)**	**207.26**	**(267.22)**
8. Other Comprehensive income(net of tax)	0.04	-	6.51	0.04	6.51
9. Total Comprehensive income/ (Loss) (7+8)	**72.37**	**37.66**	**(43.75)**	**207.30**	**(260.71)**
10. Paid up Equity share capital (face value of Rs.10 each)	1,029.30	1,029.30	1,029.30	1,029.30	1,029.30
11. Other Equity				192.34	(14.97)
12. Earnings per share (in Rupees)					
(a) Basic	0.70	0.37	(0.49)	2.01	(2.60)
(b) Diluted	0.70	0.37	(0.49)	2.01	(2.60)

Notes

1. The above Standalone financial results of the Company for the quarter and Year ended March 31, 2025 have been reviewed and recommended by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 16th May, 2025.

2. These Standalone financial results of the Company have been prepared in accordance with Indian Accounting standards (Ind AS) prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India, to the extent applicable.

3. The figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December 2024 and 31 December 2023 respectively, which was subjected to limited review.

4.Disclosure of segment wise information is not applicable, as pathology services is the Company's only business segment.

5. The previous period figures have been regrouped/rearrange/reclassified wherever necessary.

FOR **ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

Nikunj Mange
Executive Director
DIN. 08489442
Place: Mumbai
Date: 16.05.2025

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

(CIN : L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086

Tel No. 022-71975756, Email:support@aspiradiagnostics.com, Website : www.aspiradiagnostics.com

Standalone Balance Sheet as at 31 March 2025

(Rupees in Lakhs)

	Particulars	As at 31 March 2025 (Audited)	As at 31 March 2024 (Audited)
A	**ASSETS**		
	Non-current assets		
	Property, plant and equipment	207.72	266.05
	Right of Use Assets	178.42	145.68
	Goodwill	265.18	265.18
	Other Intangible assets	1.41	1.80
	Financial Assets		
	(i) Investments in associates	13.00	-
	(ii) Loans and advances	334.59	322.07
	(iii) Others	214.38	34.67
	Total non-current assets	**1,214.70**	**1,035.46**
	Current Assets		
	Inventories	51.13	44.72
	Financial Assets		
	(i) Trade Receivables	235.16	224.22
	(ii) Cash and Cash Equivalents	175.24	80.38
	(iii) Bank balances other than (ii) above	39.16	58.06
	(iv) Others financial assets	1.16	0.93
	Current tax assets (net)	19.33	15.69
	Other Current Assets	15.24	11.50
	Total Current Assets	536.44	435.51
	Total Assets	**1,751.15**	**1,470.96**
B	**EQUITY AND LIABILITIES**		
	EQUITY		
	Equity share Capital	1,029.30	1,029.30
	Other equity	192.34	(14.97)
	Total Equity	1,221.64	1,014.33
	LIABILITIES		
	Non-current liabilites		
	Financial liabilites		
	(i) Borrowings	120.64	107.72
	(ii) Lease liabilities	116.28	100.67
	Provisions	55.36	41.14
	Total non-current liabilities	292.28	249.53
	Current liabilities		
	Financial liabilities		
	(i) Borrowings	-	-
	(ii) Lease liabilities	82.68	69.82
	(iii) Trade payables		
	Total outstanding dues of micro and small enterprises	17.78	-
	Total outstanding dues of creditors other than micro and small enterprises	56.02	72.65
	(iv) Other financial liabilities	60.73	50.43
	Other current iabilities	15.30	10.98
	Provisions	4.73	3.23
			-
	Total current Liabilities	**237.23**	**207.10**
	Total Liablities	**529.51**	**456.63**
	Total Equity and Liabilities	**1,751.15**	**1,470.96**

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Nikunj Mange
Executive Director
DIN. 08489442
Place: Mumbai
Date: 16.05.2025

SARDA SONI ASSOCIATES LLP
FIRM REGN. NO. 117235
MUMBAI
CHARTERED ACCOUNTANTS

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Standalone Cash Flow Statement for the year ended 31st March 2025

(All amounts in Lakhs, unless otherwise stated)

Particulars	For the year ended 31.03.2025 (₹) (Audited)	For the year ended 31.03.2024 (₹) (Audited)
A CASH FLOW FROM OPERATING ACTIVITIES		
Profit/(Loss) for the year	207.26	(267.22)
Adjustments for:		
Interest income	(36.90)	(39.99)
Loss on Sale of Fixed Asset	(3.24)	(0.05)
Finance Costs	34.74	36.77
Depreciation and amortisation expenses	149.38	153.88
Remeasurement of defined benefit plans	0.04	6.51
Profit on lease termination	0.12	1.66
Provision for impairment of trade receivables and advances	33.38	18.21
Operating profit before working capital changes	**384.77**	**(90.22)**
Working capital adjustments:		
(Increase)/Decrease in Trade receivables	(44.32)	(8.59)
(Increase)/Decrease in Inventories	(6.41)	(4.83)
(Increase)/Decrease in other Non-Current advances	(12.75)	(8.15)
(Increase)/Decrease in Current Assets, Loans & advances and Other non-current assets	(160.81)	120.64
(Increase)/Decrease in other Current Assets	(4.27)	45.83
Increase/(Decrease) in Trade payables	1.14	38.15
Increase/(Decrease) in Provisions	15.73	5.90
Increase/(Decrease) in other Current and non-current Liabilities	4.32	0.39
Increase/(Decrease) in Other financial liabilities	10.30	6.20
CASH GENERATED FROM OPERATIONS	**187.70**	**105.30**
Taxes Paid (net of refunds)	-	-
NET CASH (USED IN)/ GENERATED FROM OPERATING ACTIVITIES(A)	**187.70**	**105.30**
B CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property , plant and equipment	(34.43)	(26.19)
Purchase of Intangible assets	-	(0.13)
(Increase)/Decrease in Investments	(13.00)	-
Proceeds from sale of fixed assets	17.11	0.15
Interest Received	36.90	39.99
NET CASH FLOW (USED IN)/ GENERATED FROM INVESTING ACTIVITIES - (B)	**6.58**	**13.83**
C CASH FLOWS FROM FINANCING ACTIVITIES		
Repayment of long-term borrowings	12.93	11.54
Repayment of short-term borrowings	-	-
Principal payment of Lease Liability	(77.61)	(70.19)
Interest paid on lease liabilities	(17.60)	(20.17)
Interest paid	(17.14)	(16.60)
NET CASH (USED IN)/ GENERATED FROM FINANCING ACTIVITIES (C)	**(99.42)**	**(95.41)**
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	94.86	23.72
Add: Cash and Cash Equivalents at the beginning of the year	80.38	56.66
Less: Cash Credits at the beginning of the year	-	-
Adjusted cash & cash equivalents at the beginning of the year	80.38	56.66
Cash and Cash Equivalents at the end of the year	175.24	80.38
Components of cash and cash equivalents comprise:		
Cash in hand	12.00	3.21
Balances with banks:		
-In Current Accounts	163.22	77.02
-In Escrow Account	0.03	0.15
-In Cash Credit Accounts	-	-
-Deposits with maturity less than 3 months	-	-
Cash and Cash Equivalents in cash flow statement	175.24	80.38

Note:

1) Cash and Cash equivalents represents cash in hand and balances with banks and Overdraft Facilities.
2) The above standalone Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard (Ind AS) 7 Statement of Cash Flows.
3)The previous period figures have been regrouped/rearrange/reclassified wherever necessary.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Nikunj Mange
Executive Director
DIN. 08489442
Place: Mumbai
Date: 16.05.2025

SARDA & SONI ASSOCIATES LLP CHARTERED ACCOUNTANTS FIRM REGN NO. 117295 MUMBAI

Sarda Soni Associates LLP
CHARTERED ACCOUNTANTS

Manoj Jain
B.Com(H), FCA, ACS, IP(ICAI), RV(S&FA)

Independent Auditor's Report on Audit of Consolidated Annual Financial Results of Aspira Pathlab & Diagnostics Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Aspira Pathlab & Diagnostics Limited

Opinion

We have audited the accompanying **consolidated annual financial results** of **Aspira Pathlab & Diagnostics Limited** (hereinafter referred to as "the Parent'), and its associates (the Parent and its associates together referred to as "the Group") for the year ended 31 March 2025, attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the audit report of the other auditor on separate audited financial statements of the associate referred to in the Other Matters section below, the consolidated annual financial results for the year ended 31 March 2025:

a. includes the result of the Aspira DNA Diagnostics Gujarat LLP

b. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

c. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net loss and other comprehensive loss and other financial information of the Parent for the year ended 31 March 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (**"SAs"**) specified under section 143(10) of the Companies Act, 2013 (**"the Act"**). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the consolidated annual financial results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained alongwith the consideration of report of the other auditor referred to in sub paragraph (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

11, Friend's Union Premises Co-operative Society Ltd., 2nd Floor, 227, P. D'Mello Road, Mumbai 400 001.
Phone: 022-2269 5289 ; Mobile: 98191 65816
Email: ssaaudit2102@gmail.com / sardasoniassociates2102@gmail.com
Nagpur (HO): "Chartered Square", Samrat Ashok Square, Saraipeth, Nagpur 400 009.
Phone: 0712-2726795, 2729471

Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Parent Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit/ loss and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

CHARTERED ACCOUNTANTS

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

— Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

— Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.

- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

— Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial result represent the underlying transactions and events in a manner that achieves fair presentation.

— Obtain sufficient appropriate audit evidence regarding the financial statements of the entities within the Group to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial statements of such entities included in the consolidated annual financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in sub paragraph (a) of the "Other Matters" paragraph in this audit report.

We communicate with those charged with governance of the Parent Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matters

a) The consolidated annual financial results include the audited financial results of one associate, Aspira DNA Diagnostics Gujarat LLP, whose financial statement reflects total assets (before consolidation adjustments) of Rs. 70.83 Lakhs at 31 March 2025, total revenue (before consolidation adjustments) of Rs. 115 lakhs, total net loss after tax (before consolidation adjustments) of Rs. 9.99 lakhs and net cash outflows (before consolidation adjustments) of Rs 3.01 lakhs for the year ended on that date, as considered in the consolidated annual financial results. . These financial statements have been audited by other independent auditors whose report has been furnished to us, and our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of this associate, is based solely on the report of such auditor and the procedures performed by us as per the guidance provided in the Standards Auditing.

   Our opinion on the consolidated annual financial results is not modified in respect of the above matter.

b) The consolidated annual financial results include the results for the quarter ended 31 March 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.



For **SARDA SONI ASSOCIATES LLP**
Chartered Accountants
Firm Reg. No. 117235W

(MANOJ KUMAR JAIN)
Partner
Membership No.- 120788
UDIN : **25120788BMIEFH2550**

Place- Mumbai
Date- 16.05.2025

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai - 400086

Tel No. 022-71975756, Email:support@aspiradiagnostics.com, Website : www.aspiradiagnostics.com

Statement of Consolidated Financial Results for the Quarter and year ended 31st March, 2025

(Rupees in Lakhs)

Particulars	Quarter ended		Year ended
	31-Mar-25 (Unaudited) (Refer Note 3)	31-Dec-24 (Unaudited) (Refer Note 3)	31-Mar-25 (Audited)
1. Income			
(a) Revenue from Operations	577.67	540.74	2,199.90
(b) Other Income	13.04	8.86	38.89
Total income	**590.71**	**549.61**	**2,238.79**
2. Expenses			
(a) Cost of Materials consumed	86.95	84.89	369.58
(b) Laboratory Testing Charges	25.09	22.41	99.65
(c) Employee benefits expense	194.41	196.57	732.62
(d) Finance Costs	9.32	9.41	34.74
(e)Depreciation and amortisation expense	36.74	38.59	149.38
(f)Other expenses	165.87	160.07	645.57
Total Expenses	**518.37**	**511.94**	**2,031.53**
3. Profit / (Loss) before exceptional items and tax (1-2)	**72.33**	**37.66**	**207.26**
4. Exceptional Items	-	-	
5. Share of profit of associates, net of tax	(4.27)	(7.05)	(5.00)
6. Profit / (Loss) before tax (3+4+5)	**68.06**	**30.61**	**202.26**
7. Tax Expenses	-	-	
8. Profit / (Loss) after tax (6-7)	**68.06**	**30.61**	**202.26**
9. Other Comprehensive income (net of tax)	0.04	-	0.04
10. Total Comprehensive income/ (Loss) (8+9)	**68.10**	**30.61**	**202.31**
11. Paid up Equity share capital (face value of Rs.10 each)	1,029.30	1,029.30	1,029.30
12. Other Equity	-	-	187.34
13. Earnings per share (in Rupees)			
(a) Basic	0.66	0.30	1.97
(b) Diluted	0.66	0.30	1.97

Notes

1. Aspira Pathlab & Diagnostics Limited (the Company" or the *Parent') and its associates (referred collectively as the 'Group') are primarily involved in providing pathology and related healthcare services.

2. The above Consolidated financial results for the quarter and year ended March 31, 2025 have been reviewed and recommended by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 16th May, 2025.

3. The figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December 2024 and 31 December 2023 respectively, which was subjected to limited review.

4. These Consolidated financial results of the group have been prepared in accordance with Indian Accounting standards (Ind AS) prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India, to the extent applicable.

5. The accompanying consolidated financial statements do not include comparative figures as this is the first occasion that Consolidated Financial Statements are being presented, hence comparative figures for the previous period have not been provided.

6.Disclosure of segment wise information is not applicable, as pathology services is the Company's only business segment.

7. The previous quarter figures have been regrouped/rearrange/reclassified wherever necessary.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Nikunj Mange
Executive Director
DIN. 08489442
Place: Mumbai
Date: 16.05.2025

SARDA SONI ASSOCIATES LLP * CHARTERED ACCOUNTANTS * FIRM REGN. NO.117235 MUMBAI

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

(CIN : L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -

Tel No. 022-71975756, Email : support@aspiradiagnostics.com, Website : www.aspiradiagnostics.com

Consolidated Balance Sheet as at 31 March 2025

	Particulars	As at 31 March 2025 (Audited)
A	**ASSETS**	
	Non-current assets	
	Property, plant and equipment	207.72
	Right of Use Assets	178.42
	Goodwill	265.18
	Other Intangible assets	1.41
	Financial Assets	
	(i) Investments	8.00
	(ii) Loans and advances	334.59
	(iii) Others	214.38
	Total non-current assets	**1,209.71**
	Current Assets	
	Inventories	51.13
	Financial Assets	
	(i) Trade Receivables	235.16
	(ii) Cash and Cash Equivalents	175.24
	(iii) Bank balances other than (ii) above	39.16
	(iv) Others financial assets	1.16
	Current tax assets (net)	19.33
	Other Current Assets	15.24
	Total Current Assets	536.44
	Total Assets	**1,746.15**
B	**EQUITY AND LIABILITIES**	
	EQUITY	
	Equity share Capital	1,029.30
	Other equity	187.34
	Total Equity	1,216.64
	LIABILITIES	
	Non-current liabilities	
	Financial liabilities	
	(i) Borrowings	120.64
	(ii) Lease liabilities	116.28
	Provisions	55.36
	Total non-current liabilities	292.28
	Current liabilities	
	Financial liabilities	
	(i) Borrowings	-
	(ii) Lease liabilities	82.68
	(iii) Trade payables	
	Total outstanding dues of micro and small enterprises	17.78
	Total outstanding dues of creditors other than micro and small enterprises	56.02
	(iv) Other financial liabilities	60.73
	Other current liabilities	15.30
	Provisions	4.73
	Total current liabilities	**237.23**
	Total Labilities	**529.51**
	Total Equity and Liabilities	**1,746.15**
		(0.00)

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Nikunj Mange
Executive Director
DIN. 08489442
Place: Mumbai
Date: 16.05.2025

SARDA SONI ASSOCIATES LLP ★ CHARTERED ACCOUNTANTS ★ FIRM REGN. NO. 117235 MUMBAI

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Consolidated Cash flow Statement for the year ended 31st March 2025	(All amounts in Lakhs, unless otherwise stated)
Particulars	For the year ended 31.03.2025 (₹) (Audited)
A CASH FLOW FROM OPERATING ACTIVITIES	
Profit before tax & share in net profit / (loss) of associates	202.26
Adjustments for:	
Interest income	(36.90)
Loss on Sale of Fixed Asset	(3.24)
Finance Costs	34.74
Depreciation and amortisation expenses	149.38
Remeasurement of defined benefit plans	0.04
Profit on lease termination	0.12
Provision for impairment of trade receivables and advances	33.38
Operating profit before working capital changes	**379.77**
Working capital adjustments:	
(Increase)/Decrease in Trade receivables	(44.32)
(Increase)/Decrease in Inventories	(6.41)
(Increase)/Decrease in other Non-Current advances	(12.75)
(Increase)/Decrease in Current Assets, Loans & advances and Other non-current assets	(160.81)
(Increase)/Decrease in other Current Assets	(4.27)
Increase/(Decrease) in Trade payables	1.14
Increase/(Decrease) in Provisions	15.73
Increase/(Decrease) in other Current and non-current Liabilities	4.32
Increase/(Decrease) in Other financial liabilities	10.30
CASH GENERATED FROM OPERATIONS	**182.71**
Taxes Paid (net of refunds)	-
NET CASH (USED IN)/ GENERATED FROM OPERATING ACTIVITIES(A)	**182.71**
B CASH FLOWS FROM INVESTING ACTIVITIES	
Purchase of property , plant and equipment	(34.43)
Purchase of Intangible assets	-
(Increase)/Decrease in Investments	(8.00)
Proceeds from sale of fixed assets	17.11
Interest Received	36.90
NET CASH FLOW (USED IN)/ GENERATED FROM INVESTING ACTIVITIES - (B)	**11.57**
C CASH FLOWS FROM FINANCING ACTIVITIES	
Repayment of long-term borrowings	12.93
Repayment of short-term borrowings	-
Principal payment of Lease Liability	(77.61)
Interest paid on lease liabilities	(17.60)
Interest paid	(17.14)
NET CASH (USED IN)/ GENERATED FROM FINANCING ACTIVITIES (C)	**(99.42)**
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	94.86
Add: Cash and Cash Equivalents at the beginning of the year	80.38
Less: Cash Credits at the beginning of the year	-
Adjusted cash & cash equivalents at the beginning of the year	80.38
Cash and Cash Equivalents at the end of the year	175.24
Components of cash and cash equivalents comprise:	
Cash in hand	12.00
Balances with banks:	
-In Current Accounts	163.22
-In Escrow Account	0.03
-In Cash Credit Accounts	-
-Deposits with maturity less than 3 months	-
Cash and Cash Equivalents in cash flow statement	175.24

Note:

1) Cash and Cash equivalents represents cash in hand and balances with banks and Overdraft Facilities.

2) The above Consolidated Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard (Ind AS) 7

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Nikunj Mange
Executive Director
DIN. 08489442
Place: Mumbai
Date: 16.05.2025

SARDA CONI ASSOCIATES LLP ★ CHARTERED ACCOUNTANTS ★ FIRM REGN. NO. [illegible] MUMBAI

Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

Date: May 16, 2025

To,
Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001.

Scrip Code: 540788
Security ID: ASPIRA

Sub: Declaration pursuant to regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

Dear Sir/ Madam,

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare and confirm that the Statutory Auditors of the Company i.e M/s. Sarda Soni Associates LLP, Chartered Accountants, (Firm Reg. No. 117235W) have issued an Audit Report on the Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2025 with unmodified opinion.

Kindly take the same on your record.
Thanking you.

For **Aspira Pathlab & Diagnostics Limited**

Balkrishna Talawadekar
Chief Financial Officer

Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

Annexure-I

Details under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. no.	Particulars	Secretarial Auditor	Internal Auditor
1.	Reason for change viz. Appointment	Appointment of M/s. Nilesh A. Pradhan & Co., LLP, Company Secretaries, Peer Reviewed Firm of Company Secretaries in Practice (FRN: L2018MH005200 & LLPIN: AAN6938) as Secretarial Auditors of the Company.	Appointment of M/s. Vishal J Bhanushali & Associates, Practicing Chartered Accountant (FRN: 145806W) as Internal Auditor of the Company.
2.	Date of Appointment & term of appointment	The Board of Directors at its meeting held on May 16, 2025 approved the appointment of M/s. Nilesh A. Pradhan & Co., LLP, as Secretarial Auditors of the Company for conducting secretarial audit for a period of five (5) consecutive years, commencing from April 1, 2025, to March 31, 2030 subject to the approval of shareholders in the ensuing Annual General Meeting.	The Board of Directors at its meeting held on May 16, 2025 approved the appointment M/s. Vishal J Bhanushali & Associates, as Internal Auditor of the Company for conducting Internal audit for a period of one (1) year, commencing from April 1, 2025, to March 31, 2026.
3.	Brief Profile	**Nilesh A. Pradhan & CO., LLP Practicing Company Secretaries:** • Established in 2001 as a proprietorship; operating as LLP since December 2018; • Peer-reviewed unit by the Institute of Company Secretaries of India (PR No:1908/2022); • Strong internal team of Company Secretaries, trainees, and employees; pan-India association with CS firms;	**M/s. Vishal J Bhanushali & Associates, Practicing Chartered Accountant:** Mr. Vishal Bhanushali, is the Partner of M/s. Vishal J Bhanushali & Associates & a member of the Institute of the Chartered Accountants of India (ICAI). They are engaged in providing quality auditing, assurance, taxation, and advisory services across different verticals to all categories of clients.

		• **Partners:** ○ Mr. Nilesh A. Pradhan, Fellow Member, ICSI, with 24 years of practice experience. ○ Ms. Prajakta V. Padhye, Fellow Member, ICSI, with 16 years of practice experience. **Key Services:** Company and LLP incorporation, Retainership, Secretarial and Due Diligence audits, Mergers & Amalgamations Consultation on Company Law, SEBI, Stock Exchange matters, Corporate Governance, Public & Rights Issues, Certification under various laws.	
4.	Disclosure of relationships between Directors	Not Applicable	Not Applicable

Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

Annexure-1

Disclosure pursuant to SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Sr. no.	Particulars	Disclosure
1.	Name of Director	Dr. Pankaj Shah (DIN:02836324)
2.	Reason of Change	The existing term of Dr. Pankaj Shah, Managing Director of the Company expires on July, 31, 2025 and the Board has extended his term for a further period of 3 years from August 01, 2025 to July 31, 2028 (both the days inclusive).
3.	Date of re-appointment and term of re-appointment	Re-appointed with effect from August 01, 2025 for a period of 3 years from August 01, 2025 to July 31, 2028.
4.	Brief Profile	Dr. Pankaj Shah has been the guiding beacon behind the entire process. His experience and expertise in the field of pathology is par excellence. His portfolio boasts of over 43 years of experience in the field of pathology. After having completed his medical sciences degree from the Government Medical college in Miraj, he completed his Diploma in Pathology and Bacteriology in 1987. His zeal for education made him pursue a Master's degree from Tata Memorial Hospital in 1987 too. He has been a consulting pathologist for the past 40 years and his experience has enriched many students and patients alike.
5.	Disclosure of relationships between Directors	He is not related to any other Director or Key Managerial Personnel (KMP) of the Company.
6.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 regarding the Director not being debarred from holding the office by virtue of any SEBI order or any other such authority.	Dr. Pankaj Shah is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.